Cheap feedstock from the US tempts chemical makers, but several hurdles stand in the way

Detailed models highlight a key role for solvents

Cement, ethanol, and ammonia makers are among those looking to convert waste carbon to cash

يُسخر النظام الحرارة الضائعة لإنتاج ما يكفي من ماء صالح للشرب لشخص بالغ لساعة واحدة

Only 13 % of oxide crystal structures obey 4 of the 5 rules simultaneously

Industry watchers say the effort is unprecedented and would not have been possible during the last SARS outbreak

Biogen will pay the biotech firm $350 million upfront and get rights to its therapies for up to 12 neurological diseases

Only 13% of oxide crystal structures obey 4 of the 5 rules simultaneously

As the founder of multiple biotech firms, C&EN's guest editor has learned a thing or two about the challenges and triumphs of starting a company. We asked her to share her best advice for budding academic entrepreneurs

Shocked to learn how little plastic gets recycled, the duo founded a company so they could make a difference

Lucy Therapeutics founder is taking an atypical approach to finding drugs for central nervous system diseases

Her company, MicroByre, is proving that wild microbes can be engineered to produce useful chemicals

Barred as a woman from becoming a brewer in India, Mazumdar-Shaw instead founded biotech firm Biocon and today focuses on affordable health care

Her company, Esya Labs, is developing DNA nanodevices that track drug responses, screen for new therapies, and more

Nanotech pioneer aims to pursue grand challenges rather than just write about them

Prolific biotech business founder says she's always on the lookout for problem-solving opportunities

Nobel Prize winner wants to solve real-world problems with directed evolution

The gene-editing tool CRISPR-Cas9 rerouted Doudna's career path. What hasn't changed for the renowned scientist and serial entrepreneur? Living and breathing the science

With guest editor Jennifer Doudna, CRISPR pioneer

Our collection of chemistry photos will help train an algorithm to recognize lab materials, vessels, and processes

Titanium-dioxide stars lance the skin with microscopic holes to allow medicine through

Ammonium salts may serve as nitrogen reservoirs on the icy bodies, suggesting a common origin for comets and the sun

The novel virus is one of the easiest virus types to deactivate, though SARS-CoV-2–specific data are lacking

Lower ozone levels led to higher grape and almond yields-and decarbonizing the state's economy could provide a further boost

Chemical makers and oil producers are pulling back on production, reconsidering investments

New study explores whether dampening IL-6 could address serious coronavirus infections

Qiagen vows to ramp up production of kits as scientists turn to social media to plea for donations

WHO does not recommend against taking the drug for fever caused by novel coronavirus infection

Boston biotech firm is making its discovery and production service available to firms working on diagnostics, treatments, and vaccines

NO₂ levels have fallen sharply in northern Italy and China

The novel virus is one of the easiest virus types to deactivate, though SARS-CoV-2-specific data are lacking

Ammonium salts may serve as nitrogen reservoirs on the icy bodies, suggesting a common origin for comets and the sun

They persist in the pharma business, even as chemical companies in the West have mostly exited

Chemistry CROs are back in business as rest of world starts to lock down

Many are FDA-approved drugs that could be repurposed

Italian workers threaten to strike, but German, UK companies and workers pull together

Old anti-malarial drugs have shown mixed results in the small clinical trials conducted so far

The nucleoside inhibitor has advantages over Gilead's remdesivir but has yet to be tested in humans

Qiagen vows to ramp up production of kits as scientists turn to social media to plea for donations

Medicinal chemists focus on the main protease of SARS-CoV-2 to develop antiviral treatments for COVID-19

Gilead Sciences' antiviral is in multiple late-stage trials to treat coronavirus infections. Don't expect a home run, say infectious disease experts

Lingering logistic problems and a sputtering economy mean hard times for companies

With a diagnostic backlog hampering disease control efforts, scientists are turning to CRISPR and other technologies to bridge the gap

These biomolecules could hold clues to why the virus is so infectious and to how to stop it

Drugmakers want to keep trials going but acknowledge that medical resources are strained

Lingering logistic problems and a sputtering economy mean hard times for companies

Editors in Europe and the US plan to work with authors whose lives and labs have been disrupted by the novel coronavirus

Fingers are being pointed in the Netherlands and the UK over reagent capacity constraints